PGNX News Alert Progenics Pharmaceuticals Inc (PGNX) 5.66 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 1:06 PM

Progenics Pharmaceuticals Inc (PGNX) 5.66 $PGNX

11.9% Return Seen to Date on SmarTrend Progenics Pharmaceuticals Call (PGNX)
Comtex SmarTrend(R) - Tue Feb 10, 9:12AM CST
SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ

GNX) on January 14th, 2015 at $6.36. In approximately 4 weeks, Progenics Pharmaceuticals has returned 11.95% as of today's recent price of $5.60.
PGNX: 5.66 (+0.06)

Progenics Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 3:30PM CST
Progenics Pharmaceuticals, Inc., (Nasdaq

GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO, is scheduled to present at the 17 Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 3:00 p.m. Eastern Time. The conference is being held at the Waldorf Astoria Hotel in New York City.
PGNX: 5.66 (+0.06)

Progenics Pharmaceuticals doses first patient in resumed study of AZEDRA in pheochromocytoma and and paraganglioma
M2 - Mon Jan 26, 4:10AM CST
Oncology company Progenics Pharmaceuticals (NasdaqGS

GNX) said on Friday that it has dosed the first subject under its resumed pivotal Phase 2 clinical study of Azedra for malignant pheochromocytoma and paraganglioma.
PGNX: 5.66 (+0.06)

Progenics resumes Azedra clinical trial
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 8:49AM CST

PGNX: 5.66 (+0.06)

Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA(TM) in Pheochromocytoma
GlobeNewswire - Fri Jan 23, 7:32AM CST
First Patient Dosed in the Resumed Study
PGNX: 5.66 (+0.06)

Actavis' Q4 Earnings to Beat Expectations, Growth Continues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 3:00PM CST
Actavis (ACT) expects fourth quarter 2014 earnings to beat Wall Street consensus estimates; the Allergan acquisition is expected to close late in the first quarter or early in the second quarter of 2015.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71)

Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:35PM CST
Actavis plc (ACT) confirmed that the U.S. Court of Appeals for the Second Circuit has granted the company's motion to expedite its appeal of a lower court ruling in Dec 2014, whereby Actavis was required to continue distribution of Namenda immediate-release (IR) tablets.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), SUPN: 8.80 (+0.22), MYL: 55.85 (+1.34)

KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), KBIO: 0.45 (+0.06), SUPN: 8.80 (+0.22)

Shares of PGNX Up 23.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 07, 11:09AM CST
SmarTrend identified an Uptrend for Progenics Pharmaceuticals (NASDAQ

GNX) on November 10th, 2014 at $5.68. In approximately 2 months, Progenics Pharmaceuticals has returned 23.42% as of today's recent price of $7.01.
PGNX: 5.66 (+0.06)

Progenics Pharmaceuticals Up 29.4% Since SmarTrend Uptrend Call (PGNX)
Comtex SmarTrend(R) - Wed Dec 31, 9:48AM CST
SmarTrend identified an Uptrend for Progenics Pharmaceuticals (NASDAQ

GNX) on November 10th, 2014 at $5.68. In approximately 2 months, Progenics Pharmaceuticals has returned 29.40% as of today's recent price of $7.35.
PGNX: 5.66 (+0.06)

Progenics Pharmaceuticals Shares Up 23.1% Since SmarTrend's Buy Recommendation (PGNX)
Comtex SmarTrend(R) - Tue Dec 16, 5:15PM CST
SmarTrend identified an Uptrend for Progenics Pharmaceuticals (NASDAQ

GNX) on November 10th, 2014 at $5.68. In approximately 1 month, Progenics Pharmaceuticals has returned 23.06% as of today's recent price of $6.99.
PGNX: 5.66 (+0.06)

Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST

SGYP: 2.98 (unch), PGNX: 5.66 (+0.06), CBST: 101.94 (+0.14), AZN: 69.96 (+0.20), SLXP: 152.35 (+3.17), NKTR: 13.54 (-0.14)

The Biggest Risks For Stocks In 2015?
Leo Kolivakis - Seeking Alpha - Fri Dec 05, 3:07PM CST
Jeff Reeves, editor of InvestorPlace.com, wrote an article for MarketWatch, 10 biggest risks to the stock market in 2015 : It is shaping up to be another great year for stocks, with the S&P 500 up about 12% year-to-date in 2014 after a roughly...
KO: 41.99 (-0.18), XLB: 51.44 (+0.43), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), TLT: 128.19 (-1.33), GSG: 21.18 (+0.43), VOO: 192.39 (+0.84), PGNX: 5.66 (+0.06), IDRA: 4.10 (-0.14), QQQ: 106.91 (+0.91), XLK: 42.65 (+0.27), IWM: 121.53 (+0.72), CL: 70.08 (+0.23), XLE: 82.04 (+1.70)

Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 5.66 (+0.06), VRTX: 113.66 (+4.03), NLNK: 38.84 (+1.51), IBIO: 0.90 (+0.36), CTIC: 2.23 (-0.02)

Progenics Pharmaceuticals Announces Presentation at RSNA Annual Meeting
GlobeNewswire - Tue Dec 02, 7:30AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq

GNX) today announced that data from the Phase 2 trial of its PSMA imaging agent candidate, 1404, will be presented at the upcoming Radiological Society of North America Annual Meeting, taking place in Chicago from November 30 - December 5, 2014.
PGNX: 5.66 (+0.06)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 5.66 (+0.06), BCRX: 10.06 (-0.09), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), IDRA: 4.10 (-0.14), QQQ: 106.91 (+0.91), SGEN: 31.57 (+0.36), XBI: 203.40 (+1.36), TGTX: 13.13 (-0.19), IBB: 323.46 (+3.04), THLD: 4.03 (+0.21), IWM: 121.53 (+0.72), TWTR: 48.50 (+0.55), XOMA: 3.41 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...